ClinicalTrials.gg
RecruitingNCT06608355Updated Nov 7, 2024

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

A Phase 1 interventional study of Human Dopaminergic Progenitor Cells in Early-onset Parkinson's Disease, sponsored by iRegene Therapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by iRegene Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Parkinsonian Disorders with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Parkinsonian Disorders · China.

Planned enrollment
14th of 14
6 · median 59
Started
2024
with 4 others
Phase 1
2 of 21
2 open now
Primary completion
2026-04
later than 4 of 16 live
Registered
9th of 21
by date
Lead sponsor
1 of 21
iRegene Therapeutics Co., Ltd.

Among the 21 studies in Parkinsonian Disorders with a site in China, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 1, reaches primary completion later than 4 of the 16 other live ones, and was the 9th registered.

Parkinsonian Disorders

218 studies on the registry are indexed under Parkinsonian Disorders; 63 are open to participants now.

Browse Parkinsonian Disorders studies →

Open to participants now

17 of the 21 studies in Parkinsonian Disorders with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Parkinsonian Disorders studies recruiting now, 18 (40%) set no upper age limit and 9 (20%) stop at 75 or younger; 4 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Parkinsonian Disorders with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment. The main questions it aims to answer are:

What medical problems do participants have when transplanting NouvNeu001 into bilateral putamen using stereotactic neurosurgery? Does injection of NouvNeu001 improve the motor function and non-motor function in participants?

Participants will:

Be injectioned the NouvNeu001 into bilateral putamen using stereotactic neurosurgery.

Take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks.

03

Conditions studied

  • Early-onset Parkinson's Disease

Keywords

  • Early-onset Parkinson's Disease
  • Dopaminergic Progenitor Cells
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years old, male or female
  • Able to understand the rationale of the clinical trial and sign form (ICF)
  • Diagnosis of Early-onset Parkinson's Disease in accordance with the MDS clinical diagnostic criteria for Parkinson's disease, and the age of onset was ≤50 years old
  • Medically suitable for neurosurgery under anesthesia and able to participate in Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) scan.
  • Hoehn-Yahr staging for "off" episodes is 2 to 4
  • The MDS-UPDRS-III score in the "off" state >30, and positive for the Acute Levodopa Challenge Test (ALCT)
  • Acceptable laboratory test results during screening and prior to transplantation

Exclusion criteria

Exclusion Criteria:

  • Atypical Parkinsonism
  • Patients who have had previous pallidotomy, striatal or extrapyramidal surgery or other brain surgery; as well as other surgical procedures that are judged by the investigator to affect patient's participation in this study; Patients with surgical or other neurosurgical contraindications
  • Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients who have brain imaging abnormalities in the striatum or other brain areas leading to a significantly increased risk for surgery
  • Patients with a history of severe cardiovascular and cerebrovascular diseases
  • Patients with a history of malignant tumors
  • Patients who have received stem cell therapy for Parkinson's disease within 2 years before signing the ICF
  • Patients with active disseminated intravascular coagulation and significant hemorrhagic tendency within 3 months prior to screening, or who cannot temporarily suspend anti- agents or other anti-coagulant medications for at least 5 days before surgery
  • Patients with long-term, heavy use of or drugs within 3 months prior to signing the ICF
  • Patients with a history of mental illness who are deemed unfit to participate in the study by the investigator; or a history of suicidal ideation or suicide attempts within the past year or currently
  • Patients who have used botulinum toxin within 6 months prior to signing the ICF
  • Patients with active epilepsy or currently on anti-epileptic drugs
  • Patients with a history of dementia or severe cognitive disorder, or the score of MDS-UPDRS 1.1 during screening is > 3; poor compliance, inability to accurately keep diary, and/or inability to sign ICF due to dementia
  • Patients with severe depression or with severe anxiety
  • Patients with the following abnormalities during screening, including: Abnormal coagulation; Abnormal immunological tests, and assessed by the investigator it is not suitable to participate in the trial; Hypertensive patients with poorly controlled blood pressure and patients with severe postural hypotension; Diabetic patients with poorly controlled blood glucose
  • Patients with other combined severe systemic diseases, such as pulmonary heart disease, moderate to severe asthma, severe (COPD)
  • Presence of one of the following: positive for (HIV) antibody, treponema pallidum antibody, virus (HCV) antibody and HCV RNA; virus (HBV) surface antigen positive and HBV DNA copy number > detection of normal values; Tuberculosis is in the active stage; Other active infections that the investigator believes may affect Patients' participation in the study or affect study outcomes
  • Patients with alcohol addiction or positive for drug of abuse testing
  • Patients with a history of contraindication or allergy to the drugs used during the study or any of its components, or are allergic to the same drugs or other macrolides, or have allergies
  • Female of who are not surgically sterilized/premenopausal/unwilling to use medically approved effective with 2 years after administration of drug and lactating women; men who are not surgically sterilized/unwilling to use medically approved effective contraception with 2 years after administration of investigational drug
  • Patients who have received electric shock therapy within 30 days prior to surgery
  • Patients who are participating in other clinical trials, or have been enrolled in other clinical studies and received intervention therapy within 3 months prior to the surgery
  • Patients with poor compliance based on clinical evaluation of the investigator
  • Patients who are being treated with drugs such as apomorphine, or levodopa/carbidopa infusion therapy
  • Patients with severe dyskinesia in both on- and off-drug states
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    NouvNeu001

    Biological: Human Dopaminergic Progenitor Cells

Interventions

  • BiologicalHuman Dopaminergic Progenitor Cells

    Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: Enrollment to 96 weeks post-transplant.

Secondary outcomes

  1. The Motor Function and Non-motor Function

    Changes in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I-IV Score from baseline. A higher score indicates more severe symptoms or worse health.

    Time frame: Baseline to 48 weeks and 96 weeks post-transplant

Other outcomes

  1. Positron Emission Tomography Imaging

    Change in uptake value from baseline using positron emission tomography (PET).

    Time frame: Baseline to 48 weeks post-transplant.

  2. Dopamine Metabolism

    Change in the levels of dopamine and its metabolites from baseline.

    Time frame: Baseline to 48 weeks post-transplant.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Apr 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2024
First posted
Sep 23, 2024
StartActual
Aug 23, 2024
Primary completionEst.
Apr 2026
CompletionEst.
Mar 2027
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06608355
Lead sponsor
iRegene Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Aug 23, 2024
Primary completion
Apr 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 7, 2024

Study contacts

Meng Cai
Contact
caimeng@iregene.com
86-027-59338180

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion